

PRESS RELEASE

Gradientech Strengthens Momentum at ESCMID Global 2026 with Multiple Abstracts and Exhibition Presence

Uppsala, Sweden, March 31, 2026. Gradientech today announces a strong presence at ESCMID Global 2026, combining multiple abstract presentations with an active exhibition. At least six abstracts featuring its rapid antibiotic susceptibility testing system, QuickMIC®, have been accepted for presentation, highlighting the growing clinical interest, adoption, and validation of the technology.

ESCMID Global, organised by the European Society of Clinical Microbiology and Infectious Diseases, is one of the most influential congresses in infectious diseases and clinical microbiology, bringing together over 16,000 professionals from around the world. The event provides a key platform for scientific exchange and industry engagement, accelerating the translation of innovation into routine clinical practice.

The accepted abstracts from Gradientech and its collaborators present new data on the performance, speed, and clinical utility of QuickMIC® across multiple relevant use cases. Together with independent evaluations, these findings demonstrate the system's potential to support faster, actionable treatment decisions and its expanding role in routine clinical workflows.

"We're very encouraged by the growing interest in QuickMIC reflected by abstracts accepted for ESCMID Global this year," says Sara Thorslund, CEO and co-founder at Gradientech. "New data and independent studies show the clinical community recognises the value of rapid AST. This external validation is a key step in establishing QuickMIC as an important tool in the fight against severe infections and antimicrobial resistance."

Discover QuickMIC® at ESCMID Global 2026

Date: 17-21 April 2026

Place: Messe München, Munich Exhibition & Congress Centre, Germany

Gradientech Booth: C32, Exhibition Hall B1

Abstract title	Presentation details
Development of a rapid susceptibility testing system for cefiderocol, aztreonam/avibactam, ceftolozane/tazobactam and meropenem/vaborbactam directly from positive blood cultures. Carrozzo F <i>et al.</i>	Poster session, P1551 Date: April 20 Time: 12:00
Impact of a new rapid antimicrobial susceptibility test in a Swedish university hospital: a retrospective analysis of time until targeted treatment. Persson S <i>et al.</i>	Poster session, P1596 Date: April 20 Time: 12:00
Deep learning model for rapid outbreak detection in a rapid phenotypic AST system. Englöf V <i>et al.</i>	Poster session, P2505 Date: April 18 Time: 12:00
Retrospective evaluation of rapid phenotypic AST in sepsis management: impact on therapeutic appropriateness, diagnostic timelines and costs compared with conventional workflow. Zappavigna A <i>et al.</i>	Poster session, P1770 Date: April 20 Time: 12:00
Comparison of piperacillin/tazobactam susceptibility testing with a Microscan system and the novel rapid system QuickMIC. López Cerero L <i>et al.</i>	Oral session, O077 Date: April 20 Time: 16:15
Electric field-mediated isolation of bacteria from positive blood cultures enables rapid AST for hard-to-isolate species and improves test performance overall. Åman A <i>et al.</i>	Poster session, P1567 Date: April 20 Time: 12:00

QuickMIC® and its Gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.

For further information, please contact:

Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80

sara.thorslund@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.